Effect of new xanthone derivatives on the level of endogenous nitric oxide in some tissue homogenates in rats by Rapacz, Anna et al.
PL ISSN 0001-530X © Polish Academy of Sciences, Cracow 2011
EFFECT OF NEW XANTHONE DERIVATIVES ON THE LEVEL 
OF ENDOGENOUS NITRIC OXIDE IN SOME TISSUE HOMOGENATES 
IN RATS
ANNA RAPACZ*1, KAROLINA PYTKA*, MAGDALENA DUDEK*, TADEUSZ LIBROWSKI*, 
KINGA SAŁAT*, BARBARA FILIPEK*, HENRYK MARONA** AND NATALIA SZKARADEK** 
* Department of Pharmacodynamics, Jagiellonian University, Faculty of Pharmacy, 
Medical College, Medyczna 9, 30-688 Cracow, Poland
** Chair of Organic Chemistry, Department of Bioorganic Chemistry, 
Jagiellonian University, Medical College, Medyczna 9, 30-688 Cracow, Poland
Accepted August 31, 2011
Nitric oxide (NO) is synthesized from L-arginine by NO synthase (NOS) in endothelial cells. It has been found that 
the levels of endogenous inhibitors of NOS, which inhibit NO synthesis, are signifi cantly increased in animals and 
patients with atherosclerosis and hypertension. Free NO is known to be involved in the central and peripheral regu-
lation of cardiovascular function. In our previous research we examined a series of new aminoalcanolic derivatives 
of xanthone, which had high antiarrhythmic and/or hypotensive activity and high affi nity for α/β1-adrenoceptors. 
We suppose that hypotensive activity could be connected with α/β1-adrenoceptor blocking properties. The aim of 
the present study was to examine the possible involvement of other mechanisms in the observed hypotensive pro-
perties so we assessed the involvement of the most active xanthone derivatives in the NO pathway. We measured 
the infl uence of new xanthone derivatives on the level of endogenous nitric oxide in some tissue homogenates using 
Griess’s method. However, none of the tested compounds signifi cantly increased the NO level in the heart, liver, 
kidney or brain tissues, as compared with the control. The results indicate that the mechanism of the hypotensive 
action of the examined new xanthone derivatives is not connected with the release of endogenous NO. 
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INTRODUCTION
Xanthones are a class of heterocyclic compoun-
ds, widely distributed in nature. Nowadays, xan-
thones and xanthone derivatives are isolated from 
plants or synthesized chemically. They exhibit a va-
riety of biological activities, including anti-infl am-
matory, anti-platelet aggregation, antithrombotic, 
vasorelaxant, antitumor and antimicrobial activi-
ties. The pharmacological properties of xanthones 
in the cardiovascular system have attracted great 
interest. Xanthones and xanthone derivatives have 
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been shown to possess benefi cial effects on some 
cardiovascular diseases, including ischemic heart 
disease, atherosclerosis, hypertension and throm-
bosis. Xanthonoids isolated from Gentianaceous 
plants have been proved to be potent inhibitors of 
platelet aggregation and vasoconstriction (LIN et al., 
2009). Moreover, a series of synthetic xanthone de-
rivatives have been shown to possess high hypo-
tensive activity in rats (MARONA et al., 2008; WANG 
et al., 2002). Among many interesting properties, 
xanthones show strong antioxidant activity due to 
the presence of hydroxy groups and/or a catechol 
moiety at key position. Oxygenated and prenyla-
ted xanthones, extracted from mango, have been 
shown to be powerful antioxidants in animals and 
humans (SANTOS et al., 2011). Inhibition of endoge-
nous nitric oxide synthase (NOS) inhibitors by xan-
thones may be responsible for enhancing endothe-
lium function and reduction of events associated 
with atherosclerosis (JIANG et al., 2004).
In our previous research we examined a series of 
new aminoalcanolic derivatives of xanthone, which 
had high antiarrhythmic and/or hypotensive activi-
ty and high affi nity for α/β1-adrenoceptors (MARONA 
et al., 2008a, 2009). We suppose that hypotensive 
activity could be connected with α/β1-adrenoceptor 
blocking properties. It is known that most classic 
β-blockers, classifi ed according to Vaughan Wil-
liams as second-class antiarrhythmic drugs, and 
hypotensive drugs contain a 1-aroxy-3-alkylami-
no-2-propanol group in their structure (proprano-
lol, atenolol, metoprolol, acebutolol). Furthermore, 
the 1-aroxy-3-alkylamino-2-propanol group is a 
structural element of some third-generation non-
selective β-blockers with additional α-adrenolytic 
properties (carvedilol) which have benefi cial blood-
pressure-lowering effects. Moreover, nebivolol, a 
third-generation β-blocker, offers a unique mix 
of β1-selectivity and NO-mediated vasodilatation. 
Nebivolol is a racemic mixture of L-nebivolol and 
D-nebivolol. The D-isomer appears to be respon-
sible for the β-blocking effects of the drug, while 
the L-isomer stimulates endothelial nitric oxide 
synthase (eNOS) without having a signifi cant ef-
fect on β1-receptors at therapeutic doses. Although 
the mechanisms responsible for the drug actions 
on nitric oxide are controversial, several theories 
have been suggested, including agonistic effects on 
β3-receptors, stimulation of endothelial adenosine 
triphosphate effl ux and activation of eNOS via bin-
ding to β2-receptors (DERY et al., 2011).
The aim of the present study was to examine 
the possible involvement of other mechanisms 
in the observed hypotensive properties. For that 
purpose we assessed the involvement of the most 
active xanthone derivatives in the NO pathway. 
Free NO is known to be involved in the central 
and peripheral regulation of cardiovascular fun-
ction (HINK et al., 2003; NAPOLI and IGNARRO, 2009; 
SY et al., 2001).
MATERIAL AND METHODS
Drugs
The investigated xanthones MH-82 (5-(3N-(2-ami-
no-2-methyl-1-hydroxypropyl)-2-hydroxypropo-
xy)-3-chloro-9H-xanthen-9-one hydrochloride), 
MH-87 (4-(3-(Allylamino)-2-hydroxypropoxy)-9H-
xanthen-9-one hydrochloride), MH-89 (2-(3-(Al-
lylamino)-2-hydroxypropoxy)-9H-xanthen-9-one 
hydrochloride) and MH-97 (4-(3N-(2-Amino-2-
methyl-1,3-dihydroxypropyl)-2-hydroxypropo-
xy)-9H-xanthen-9-one hydrochloride) were syn-
thesized at the Chair of Organic Chemistry, 
Department of Bioorganic Chemistry, Jagiellonian 
University, Medical College in Cracow (MARONA et 
al., 2009). The chemicals used were: Heparin so-
dium (Heparinum, Polfa S.A., Poland), Tiopental 
sodium (Thiopental Natrium, HEFA-Frenon Arzei-
mittel, Germany), Sulfanilamide (Sigma-Aldrich, 
Germany), N-(1-naphtyl)-ethylenediamine (Sigma-
Aldrich, Germany), Folin-Ciocalteau reagent (Sig-
ma-Aldrich, Germany); other chemicals used were 
obtained from Polish Reagent Company (P.O.C.H., 
Poland). All the chemicals were of pro analysis 
grade. The investigated and reference compounds 
were suspended in saline.
Animals
The animals used for the tests came from the Ani-
mal Breeding Farm of the Faculty of Pharmacy, 
Medical College, Jagiellonian University. Wistar 
albino male rats weighing 150-200 g were used 
for the tests. The animals were housed and fed 
in a laboratory and kept at constant temperature 
of 22°C under standard conditions with natural 
light-dark cycles. Each experimental group con-
sisted of 4-6 animals and all the animals were 
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used only once. The treatment of the laboratory 
animals used in the present study was in full ac-
cordance with the respective Polish and European 
regulations and was approved by the Local Ethics 
Committee.
Statistical analysis
All the data are expressed as mean ± SEM. The 
level of statistical signifi cance was determined by 
analysis of variance (ANOVA test).  Differences 
were considered signifi cant when p < 0.05.
Infl uence on the NO pathway
Blood pressure was measured in thiopental-ane-
sthetized rats before and after intravenous ad-
ministration of the investigated compounds (10 
mg/kg b.w.) over a period of 15 minutes in all the 
groups. The left carotid artery was cannulated 
with polyethylene tubing fi lled with heparin solu-
tion in saline to facilitate pressure measurements 
made using Datamax apparatus (Columbus In-
struments, Ohio). Subsequently, the animals were 
sacrifi ced. Blood was collected to heparinized tu-
bes, centrifuged (286 x g, 10 min), and plasma 
was stored at – 800C. The livers, brains, hearts 
and kidneys were removed, washed in 0.9% NaCl, 
placed in liquid nitrogen and stored at -800C until 
needed for biochemical tests.
Preparation of tissue homogenates
The frozen tissues were weighed and homogena-
tes were prepared by homogenization of 1 g of 
the tissue in 4 ml of 0.1 M phosphate buffer, pH 
7.4 using IKA-ULTRA-TURRAX T8 homogenizer. 
Next, the homogenates were used for nitric oxide 
assay.
Determination of nitrate
NO was measured using Griess’s method (TSIKAS, 
2007). The fi nal products of NO in vivo are nitri-
te (NO2
-) and nitrate (NO3
-). Nitrite (NO) levels were 
measured in the homogenates or plasma. Briefl y, 
750 μl of redistilled water and 250 μl of tissue sam-
ple were placed in a water bath at 100oC for 15 
min. After cooling, the samples were centrifuged 
at 10000 x g for 10 min. Nitrite determination: 75 μl 
of the supernatant and 75 μl of redistilled water were 
incubated for 30 min at room temperature. After this 
time, the absorbance was measured at 492 nm. Then, 
50 μl of Griess reagents [sulfanilamide (1% solution 
in 2.5% H2PO3) and N-(1-naphtyl)-ethylenediamine 
(0.1% solution in 2.5% H2PO3)] were added and af-
ter 15 min the absorbance was measured at 492 
Fig. 1. Effects of the compounds and the reference compound 
NTG on the NO level in the rat heart.
Each value represents mean ± SEM. Statistical signifi cance 
was evaluated using a one-way ANOVA test: ***p<0.001.
Fig. 2. Effects of the compounds and the reference compound 
NTG on the NO level in the rat liver. 
Each value represents mean ± SEM. Statistical signifi cance 
was evaluated using a one-way ANOVA test: ***p<0.001.
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nm. The results were calculated from the standard 
curves obtained for sodium nitrite solutions (10 
– 150 μM).
Determination of proteins
Proteins were measured using Lowry’s method 
(LOWRY et al., 1951). This method is based on the 
reaction of peptide bonds and aromatic amino acid 
residues of proteins with Folin-Ciocalteau reagent 
(a mixture of phosphotungstic acid and phospho-
molybdenic acid) in an alkaline environment in the 
presence of cupric ions. Copper (II) ions bound to 
protein tyrosine and tryptophan residues reduce the 
above acids to oxides. Absorbance was measured 
at 500 nm. A 1% solution of bovine albumin was 
used to prepare a standard curve.
RESULTS
Nitroglycerine – the reference compound – signi-
fi cantly increased the NO levels in the tissues of 
the following organs: heart - about 68 % (control 
- 1.73+0.003 μM), liver - about 168 % (control - 
1.10+0.007 μM), kidney - about 457 % (control - 
0.89+0.011 μM), and brain - about 71 %. None of 
the tested compounds signifi cantly increased the 
NO level in the heart, liver, kidney or brain tissues 
as compared with the control (100 %). These re-
sults indicate that the mechanism of hypotensive 
action of the examined new xanthone derivatives 
is not connected with the release of endogenous 
NO (Fig. 1, 2, 3, 4). 
DISCUSSION
Pharmacological research on the new xanthone 
derivatives with potential biological properties has 
remained the area of our interest for the past seve-
ral years and has been documented by a number 
of publications. In our previous research we exa-
mined a series of new aminoalcanolic derivatives 
of xanthone which exhibit high antiarrhythmic 
and/or hypotensive activity and high affi nity for 
α/β1-adrenoceptors (MARONA et al., 2009). Additio-
nally, we examined their two aminic analogues. 
Aminoalcanolic moieties are well-known structu-
ral elements of β-blockers. It is obviously known 
that the mechanism of action of nebivolol – the 
third-generation β-blocker – is also connected 
with the involvement of the NO pathway. Drugs 
that increase NO production can lead through 
this mechanism to vasodilation. It is an impor-
tant mechanism of action because abnormalities 
in nitric oxide-mediated endothelial vasodilation 
are risk factors for atherosclerosis, hypertension 
or diabetes (BACRIS et al., 2010; KAMP et al., 2010). 
Fig. 3. Effects of the compounds and the reference compound 
NTG on the NO level in the rat kidney.
Each value represents mean ± SEM. Statistical signifi cance 
was evaluated using a one-way ANOVA test: ***p<0.001.
Fig. 4. Effects of the compounds and the reference compound 
NTG on the NO level in the rat brain.
 Each value represents mean ± SEM. Statistical signifi cance 
was evaluated using a one-way ANOVA test: ***p<0.001.
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Xanthone derivatives can also act through the NO 
pathway. It has been shown that N-nitro-L-argini-
ne methyl ester (L-NAME) – which  is a NOS inhi-
bitor and therefore leads to complete inhibition of 
NO production – inhibits endothelium-dependent 
action of xanthone derivatives (WANG et al., 2007). 
Nitric oxide is synthesized from L-arginine by NO 
synthase (NOS) in endothelial cells. It has also 
been found that endogenous inhibitors of NOS, 
such as asymmetric dimethylarginine (ADMA), 
which inhibit NO synthesis, are signifi cantly in-
creased in animals and patients with atheroscle-
rosis. ADMA has been thought to be a key factor 
contributing to endothelial dysfunction. The pro-
tective effect of xanthones on the endothelial cells 
could be related to a decrease in ADMA concentra-
tion (JIANG et al., 2003). However, in our study the 
examined compounds did not increase the level 
of NO in tissues as compared with the control. In 
conclusion, the results of this study suggest that 
hypotensive activity of the tested xanthone deriva-
tives is connected with high affi nity for α/β1-adre-
noceptors but not with the release of endogenous 
nitric oxide. 
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